ELAN Shares Move Closer to Their 52 Week High.

Elanco Animal Health stock is trading -7.68% below its average target price of $19.53 after marking a 1.6% during today's morning session. Analysts are giving the Mid-Cap Pharmaceutical company an average rating of buy and target prices ranging from $16.0 to $23.0 per share.

The stock has an average amount of shares sold short at 5.5%, and a short ratio of 3.37. Only 0.66% of the company's shares are owned by insiders, indicating that management does not have a deep alignment of interest with its shareholders. Finally, we also note that a significant number of institutional investors are invested in the stock, with 99.3% of Elanco Animal Health's shares being owned by this investor type.

Institutions Invested in Elanco Animal Health

Date Reported Holder Percentage Shares Value
2024-03-31 Dodge & Cox Inc 17% 83,848,850 $1,511,794,823
2024-03-31 Primecap Management Company 11% 52,885,068 $953,517,812
2024-03-31 Vanguard Group Inc 10% 49,258,240 $888,126,101
2024-03-31 Blackrock Inc. 5% 26,639,783 $480,315,305
2024-03-31 Price (T.Rowe) Associates Inc 4% 22,139,018 $399,166,509
2024-03-31 Black Creek Investment Management Inc. 4% 20,159,435 $363,474,626
2024-03-31 Dimensional Fund Advisors LP 4% 17,995,962 $324,467,207
2024-03-31 Citadel Advisors Llc 2% 12,081,728 $217,833,564
2024-03-31 Shapiro Capital Management Company, Inc. 2% 10,893,298 $196,406,170
2024-03-31 Ancora Advisors, LLC 2% 10,641,194 $191,860,735

Besides an analyst consensus of some upside potential, other market factors point to there being mixed market sentiment on Elanco Animal Health.

The above analysis is intended for educational purposes only and was performed on the basis of publicly available data. It is not to be construed as a recommendation to buy or sell any security. Any buy, sell, or other recommendations mentioned in the article are direct quotations of consensus recommendations from the analysts covering the stock, and do not represent the opinions of Market Inference or its writers. Past performance, accounting data, and inferences about market position and corporate valuation are not reliable indicators of future price movements. Market Inference does not provide financial advice. Investors should conduct their own review and analysis of any company of interest before making an investment decision.